Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Aphria Inc. APHA

Aphria, which is headquartered in Ontario, produces and sells medicinal and recreational cannabis. The company operates through retail and wholesale channels in Canada and internationally. Aphria is a main distributor of medical cannabis to Germany and has operations in over 10 countries outside of Canada. However, it does not have exposure to the U.S. CBD or THC markets due to the constraints... see more

NDAQ:APHA - Post Discussion

Aphria Inc. > Gentleman's bet on q4 results
View:
Post by hevin on Jul 17, 2020 1:34pm

Gentleman's bet on q4 results

Guessing Net revenue of 150 million with a tiny loss of .02 because of alEFIA settlement. Anyone else?
Comment by RandomCommenter on Jul 17, 2020 1:48pm
Simon will announce executive bonuses and an increase to his annual salary as an integral part of his...Aphria's future.
Comment by Robeyy18 on Jul 17, 2020 2:00pm
Been wondering to what extent EU GMP certification will help CC Pharma margins if at all this quarter?  Revenues were 88 million last quarter and they've also been approved for a small amount of growing capacity in Germany so it could be impactful.  Revenues should remain consistent or marginally higher in the German market seeing as pharmacies were considered esseential and patients ...more  
Comment by Steve0123 on Jul 17, 2020 2:02pm
Settlement won't affect q4. 
Comment by TheWokeLemming on Jul 17, 2020 2:41pm
Revenues of $175-185 million is my guess Anyone know what % of Canadian sales Aphria had as of last quarter?   I believe I read 18% somewhere.  Canadian sales for May will give us some clarity.   Hopefully it’s above April’s $180 million.  
Comment by ilvmyt5s on Jul 17, 2020 3:08pm
I'll take $+199,999,999 and over. BoB  Just got OCS. The sales order was ERP# 2,105,nnn
Comment by ilvmyt5s on Jul 17, 2020 3:31pm
off the cuff... before the pandemic it was ERP#500,000 end of May it was ERP# 2,000,000 ~ 150,000,000 sales orders Aphria's ON market share is 12%.    150,000,000 x .12=18,000,000 Say ~ $25 per order. 18,000,000 x $25= $450,000,000   In Ontario, Aphria made $450,000,000 in q4 2020 ????
Comment by Robeyy18 on Jul 17, 2020 3:36pm
wondering what how influential the uptick in vape usage might be as aphria has done well in that market.
Comment by ilvmyt5s on Jul 17, 2020 3:51pm
off the cuff... before the pandemic it was ERP#500,000 end of May it was ERP# 2,000,000   1,500,000 sales orders   Aphria's ON market share is 12%.    1,500,000 x .12=180,000 Say ~ $25 per order. 180,000 x $25=4,500,000 In Ontario, Aphria made $4,500,000 in q4 2020 
Comment by ilvmyt5s on Jul 17, 2020 3:59pm
Say ~ $100 per order. 180,000 x $100=$18,000,000 In Ontario, Aphria made $18,000,000 in q4 2020 
Comment by ilvmyt5s on Jul 17, 2020 4:13pm
Alberta is the largest Cannabis market in Canada. Assuming Aphria's 12% is the same in each province.  ~ $40,000,000 from Alberta and Ontario CC pharma is good for $100,000,000  thats $140,000,000 from CCPharma + Alberta + Ontario   they gotta do $60,000,000 from the rest to be over $200,000,000 for Q4 2020   It's gonna be close...
Comment by Robeyy18 on Jul 17, 2020 3:31pm
couldn't find anything on market share.  if we assume may stays consistent at 180 million and aphrias market share is indeed 18% that would provide them with revenues of roughly 97 million.  throw in another 90 million or so from cc pharma and the higher end of your estimate looks pretty accurate.
Comment by TheWokeLemming on Jul 17, 2020 3:45pm
Thx Robeyy.  If CCPharma made $88m Q3, then Cdn revenue was $56m on $450m Cdn Sales.  That’s only 12.4%.  If Cdn May comes in at $180m, then it’s $540m for Q4.  12.4% of that is $67m.   I’m assuming growth in Germany to match Canada, which would be 20%.  That bumps revenue to $105 Cdn.  Add $67m and it’s $172m for the quarter.  Now perhaps CCPharma doesn’t ...more  
Comment by gottahunch on Jul 17, 2020 5:17pm
Alefia will impact next q results, not this one. I have revenue at 70 M cannabis and in, rec/med/Latam and cc pharma at 101. However, pantry loading during pandemic could cause CC to be even higher, maybe 10 m or so.
Comment by Sneekyboots on Jul 17, 2020 5:20pm
Gottaclown get a life 
Comment by hevin on Jul 17, 2020 6:15pm
We hope you're true to your name gottahunch!
Comment by arblines on Jul 17, 2020 6:23pm
I think Aphria's earnings will come in at 170mil for the quarter; 560mil for the year just shy of the 575mil estimate. My guess is Aphria will post a loss for the quarter, but profitable for the year. I hope they will release guidance of 1 billion in revenues for FY2021 with 100mil EBITDA, and hopefully the SP will be in the 9$ to 12$ range again.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities